Work

A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.2585

Authors: Rachel E. Sanborn, Rodolfo Eduardo Bordoni, Gini F. Fleming, Mustafa Khasraw, Thomas Hawthorne, Lawrence J Thomas, Tracey Rawls, Diane C. Young, Philip Golden, Tibor Keler, Michael Jay Yellin

Institutions: Providence Portland Medical Center, Georgia Cancer Specialists, University of Chicago, Duke Medical Center, Duke Cancer Institute, Celldex Therapeutics (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3173067903

Cites:

Cited by: 6

Related to: 10